Precision radiolabeled B-cell maturation nanobody for targeted PET imaging and radioligand therapy of disseminated multiple myeloma.

ABSTRACT: Background: Multiple myeloma (MM) is an incurable plasma cell malignancy with limited disease-specific imaging options. Current diagnostic methods often fail to detect early disease states and minimal residual disease, highlighting the need for more precise molecular imaging and targeted therapeutic approaches. We developed a radiolabeled nanobody targeting B-cell maturation antigen (BCMA) to enable both high-contrast molecular imaging and targeted radioligand therapy in human MM models. Methods: A high-affinity anti-BCMA nanobody was labeled with [¹⁸F]FPy-pyridine prosthetic group for PET imaging and [¹³¹I]I for radioligand therapy. Target expression and in vitro binding affinity and specificity were assessed using biolayer interferometry, flow c

SUBMITTER: Ghaemi B 

PROVIDER: S-EPMC12775650 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature